Vortex Biosciences

Vortex Biosciences is a private, commercial-stage diagnostics company pioneering a unique microfluidic platform for the label-free, gentle capture of viable circulating tumor cells (CTCs). Founded in 2012 and headquartered in Cambridge, UK, with a new laboratory in Manchester, the company is positioned at the forefront of the liquid biopsy market, enabling multi-omics analysis of CTCs for research and clinical applications. Key milestones include the launch of its VTX-1 system, a clinical study to advance cancer monitoring, and a strategic partnership with AstraZeneca through an exchange program. The company is leveraging its technology to support precision oncology by providing a real-time, functional view of cancer progression and treatment resistance.

Inertial microfluidics for label-free, reagent-free isolation of viable circulating tumor cells (CTCs) from whole blood. The VTX-1 system uses a disposable cartridge to trap larger CTCs in microscale vortices, preserving them for downstream multi-omics analysis.

Vortex competes in the crowded liquid biopsy market against major players focused on ctDNA (e.g., Guardant Health, Freenome) and other CTC capture technologies that use filter-based or antibody-dependent methods (e.g., Menarini Silicon Biosystems' CellSearch). Its key differentiation is the label-free, gentle isolation of viable cells enabling functional assays, a niche with fewer direct competitors.